Geraldine O’Sullivan Coyne MD., PhD., MRCPI., is a Clinical Investigator at START Dublin and a Consultant Medical Oncologist at the Mater Misecordiae University Hospital (MMUH) in Dublin, Ireland. She completed her General Medicine training together with her PhD (Molecular Medicine) followed by Medical Oncology training in Ireland prior to further clinical fellowships in Hematology/Oncology and Advanced Developmental Therapeutics at the National Cancer Institute, National Institutes of Health, USA.

She was appointed as Staff Clinician in the Developmental Therapeutics Clinic (DTC), Early Clinical Trials Development Program at NCI in 2016. She received her Associate Research Physician appointment in 2020 and became the Head of the Clinical Sciences Section until leaving the NIH in 2023. She led several early phase clinical trials at the Developmental Therapeutics Clinic.

During her time at DTC one of her research focuses was DTC’s sarcoma and rare tumors initiatives including the ongoing partnership with the Pediatric Oncology Branch (POB) at NCI for the enrollment of young adult patients with solid malignancies, NF1 and inoperable plexiform neurofibromas and/or malignant peripheral nerve sheath tumors (MPNST), in early phase trials as well as collaboration with the Surgery Branch at NCI for patients with peritoneal carcinomatosis.

She returned to Ireland in 2023 and is an active member of various scientific groups both in Ireland and internationally, and is also part of the Clinical Trials Research Unit at MMUH as an associate investigator in a number of late phase trials. She is a Clinical Investigator with the new START Dublin site, Ireland’s first early phase clinical trials unit. She has received numerous awards on both sides of the Atlantic for her work to date and has authored over 100 published works.